The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Open accessAbstract
Radiotherapy plays a central part in curing cancer. For decades, most research on improving treatment outcomes has focused on modulating radiation-induced biological effects on cancer cells. Recently, we have better understood that components within the tumour microenvironment have pivotal roles in determining treatment outcomes. In this Review, we describe vascular, stromal and immunological changes that are induced in the tumour microenvironment by irradiation and discuss how these changes may promote radioresistance and tumour recurrence. We also highlight how this knowledge is guiding the development of new treatment paradigms in which biologically targeted agents will be combined with radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Generation of intratumoral O2 is also feasible to improve the efficacy of radiotherapy by using bioactive albumin-MnO2 nanoparticles [94].”
From Hypoxia Signaling in Cancer: From Basics to Clinical Practice (2021) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedMMP-2 siRNA Inhibits Radiation-Enhanced Invasiveness in Glioma Cells
Badiga, A. V., Chetty, C., Kesanakurti, D., Are, D., Gujrati, M., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020614 · Cited by 110
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,005 of 1,005
Wang, D., Lin, S., Li, T., Yang, X., Zhong, X., Chen, Q., Jiang, G., & Li, C. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101275 · Cited by 18
“This may be one of the significant reasons why a single radiotherapy treat-ment rarely induces a strong anti-tumor immune response clinically [26, 27].”
BackgroundShin, S., Bae, G.-H., Park, J. D., Koh, E.-Y., Ko, S., Han, J., Park, C. G., Kim, D.-H., Na, K., & Park, W. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124002 · Cited by 8
Li, M., Lin, L., Guo, T., Wu, Y., Lin, J., Liu, Y., Yang, K., & Hu, C. (2021) · BioMed Research International · doi:10.1155/2021/9262453 · Cited by 7
“Hypoxic cells demonstrate high radiation tolerance and resist tumor stem cell DNA damage [29].”
BackgroundBrunel, A., Samain, R., Neuzillet, C., & Bousquet, C. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.09 · Cited by 5
“Tumor stroma heterogeneity also ensues from its constant evolution during tumor progression or remodeling under treatments, and from inconsistent spatial distribution into the tumor of stromal components (6-8).”
BackgroundZeng, B., Ling, K., Yuan, Q., Chen, Z., Zhang, G., Kang, W., Zheng, X., Liao, C., Mai, Y., Huang, Z., et al. (2026) · Theranostics · doi:10.7150/thno.124034 · Cited by 7
Metadata
- Authors
- Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J.
- Affiliations
- Institute of Cancer Research (GB)
- Corresponding author
- Barker, Holly E.
- Venue
- Nature Reviews Cancer
- Published
- 2015-06-24
- Volume
- 15
- Issue
- 7
- Pages
- 409-425
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4896389
- OpenAlex
- W1912124796
- Cited by
- 2,144
- References
- 200
- Citations by year
- 2026: 181 · 2025: 215 · 2024: 246 · 2023: 242 · 2022: 249 · 2021: 256 · 2020: 230 · 2019: 175 · 2018: 161 · 2017: 119 · 2016: 63 · 2015: 7
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-24)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (C46 ⁄ A10588, C7224/A13407, A13407, 13407)
- National Institute for Health and Care Research (CL-2014-22-003)
- Rosetrees Trust
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor microenvironment, radioresistance (biology), radiotherapy, tumor stroma, tumor recurrence, vascular changes, immunological changes, combination therapy, molecularly targeted agents
- MeSH terms
- Animals, Fibroblasts, Humans, Immune Tolerance, Neoplasm Recurrence, Local, Neoplasms, Radiation Tolerance, Cell Hypoxia, Transforming Growth Factor beta, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
